Cepheid (CPHD $31.40)-Good Entry Point For Long Term
Cepheid in Low $30's- Long Term Buy Cepheid is not a cheap stock with a Price to Sales of 6.82, market cap of $2.10B and a forward PE of 122.58 but we see a capitulation of sellers who were playing the MO game with a very expensive stock. Nonetheless Cepheid is a high quality Company and a...
NASDAQ Correction Hits Biotechnology Stocks: Update 1 10/24
Biotech At Risk: Take a Little Off Speculative Stocks Biotechnology remains one of the strongest sectors of 2012 especially earnings driven, large cap stocks all doing well today: Amgen (AMGN $88.4) up 1%, Biogen (BIIB $142.6) up 0.4% and Gilead (GILD $68.85) up 6%. Biogen Idec earnings are...
Rayno Life Sciences: Investor Election Guide from Credit Suisse
Ultimate Presidential Election Guide Click above for an interesting sector and stock review from Credit Suisse including major positions of candidates. Stocks in the Rayno Life Sciences Portfolio that were mentioned on the "Obama Victory" side include: Illumina (ILMN) and ThermoFisher (TMO) On...
Will The Biotechnology Bull Market Stimulate Venture Investing?
Notes from the BioInvestor Forum October 9-12--Biotech Investing The BioInvestor Forum held every year at this time in San Francisco is one of the premier events for emerging companies. Over 500 investors and companies attended with 7 major sessions on investing and innovation trends. Over 100...
Rayno Life Science DX and Tools Update: EXAS
Exact Sciences (EXAS) is down about 8% to $10.65 on heavy volume after a Wedbush Downgrade to Neutral. Preliminary data coming next week. The stock was added to the Rayno Life Sciences Portfolio on 12/10/10.Barron's had a positive article on Oct 6 and the Company raised $58M in August with a...